Hello, my name is Erik Frank and I finished my professional training as a wholesaler and foreign trader at Transo-Pharm Handels-GmbH in January 2021.
Vocational education in Germany takes largely place in a dual education system, in which the trainees are employed in a company and complete the practical part of their training there, while they attend vocational business school, where the theoretical part takes place. The training ends after three years, but due to good grades I was able to shorten it to two and a half years.
We would like to thank you sincerely for your trust and cooperation throughout the year.
2020 was a year full of unfamiliar challenges. Living through a pandemic showed us here at Transo-Pharm that business relations not only consists of successful projects and “numbers”. It´s the emotional part that´s missing when fairs and in-person meetings are canceled. We hope that we can all meet again soon.
The entire Transo-Pharm team wishes you a wonderful Christmas Season and a Happy New Year.
Alkaloids produces two grades on a commercial basis: non-micronized and micronized material.
The existing CEP has been amended and now includes the micronization step, hence the current version No. R1-CEP 2010-298-Rev 01 covers now both grades, micronized and non-micronized material. The revision also includes editorial updates and notifications. We believe this new version represents a significant improvement over the previous version and will support our customers with their drug product registrations.
The micronization step is done in-house. Importantly, the micronized material from Alkaloids does not require any special cooling during transportation or storage.
Enantiomeric purity – and the associated advantages of Transo-Pharm’s Epinephrine (synonym = Adrenaline)
Enantiomeric purity in chiral molecules – such as Transo-Pharm’ s Epinephrine Base and Bitartrate – have been in the focus of the health authorities for some time now. Transo-Pharm is well prepared to fully satisfy the more stringent requirements with their state-of-the-art stereo-selective manufacturing process. Transo-Pharm is therefore in the position to achieve an Enantiomeric Excess (ee) of 99% in commercial production for several years now. This is a significant contribution to ensure patient safety.
Please find the full article below. Learn more about the science behind this topic.